KR19990081594A - New Use of Polysaccharide Materials Isolated from Felinus Linteus - Google Patents

Abstract

The present invention relates to the use of a polysaccharide material isolated from a strain of the genus Pelinus, in particular Pelinus linteus Yoo KCTC 0399BP, as an anti-cancer therapeutic agent.

The present invention can be used as a drug for the prevention, treatment and basic mechanism research of immune-related diseases such as cancer and AIDS, since the polysaccharide material isolated from the Felinus linteus milk strain inhibits cancer metastasis by mediating the in vivo immune function. Excellent effect.

Description

Novel Use of Polysaccharides Isolated from Felinus Linteus

The present invention relates to a novel use of polysaccharides isolated from Pelinus linteus as an anticancer drug. More specifically, the present invention relates to the separation of polysaccharides from Felinus linteus and to providing these polysaccharides as drugs for the prevention, treatment and basic mechanism research of immune related diseases such as cancer and AIDS.

Chemotherapy, radiotherapy, and surgery are used to treat cancer, but these therapies can effectively remove solid cancer, but cannot completely cure cancer. The therapeutic effect is low for metastasis. In addition, chemotherapy and radiation therapy by treatment with anticancer agents such as adriamycin cause severe side effects. In order to reduce side effects, the amount of anticancer drugs can be reduced to treat cancer, but in this case, the therapeutic effect is lowered. A bigger problem is that it does not inhibit cancer metastasis after chemotherapy as described above. Therefore, conventional chemotherapy has the effect of inhibiting the growth of cancer cells, but did not cure the cancer. Recently, immunotherapy is used in combination with chemotherapy to increase anticancer effects and reduce side effects. In other words, the combination of immunostimulants and anticancer drugs such as adriamycin (immunochemotherapy) to reduce side effects and increase the anticancer effect. Substances used in immunotherapy include cytokines such as interleukin-2. Interleukin-2 has an excellent therapeutic effect as an immunotherapy agent, and especially shows an excellent therapeutic effect on cancer metastasis. However, if the cancer treatment applied to the human body should be used in high concentrations at this time has the disadvantage of causing severe side effects. Recently, retinan, OK-432, etc. have been developed as immunopotentiators other than cytokines, and these substances have anti-cancer effects without side effects.

Felinus linteus, a type of basidiomycetes, is called a situation in oriental medicine and is used as a valuable medicine in the private sector due to its large therapeutic effect on various diseases, especially tumors. The inventors of the present invention, while studying the immunological activity of polysaccharides isolated from Felinus linteus, found that Felinus linteus has anticancer activity.

Therefore, an object of the present invention is to provide a polysaccharide material having anticancer activity from Felinus linteus. Another object of the present invention is to provide a polysaccharide material isolated from Felinus linteus as a new use as a drug for the prevention, treatment and basic mechanism research of immune related diseases including cancer.

The object of the present invention was to examine the constituent monosaccharides and structural characteristics of the polysaccharide material after culturing the Pelinus linteus strain by extracting and separating the material containing the polysaccharide from the strain. Mice transplanted with skin cancer cells were treated with the polysaccharide material to investigate anticancer activity. In the same way, the anticancer activity was investigated by using the polysaccharide material and chemicals in combination. Subsequently, skin cancer cells were implanted into the tail vein and treated with chemicals and the polysaccharides to investigate their effects on cancer metastasis, and the different mechanisms of the anticancer effects exhibited by the chemicals and the polysaccharides were investigated.

1 is a graph showing the change over time of the culture characteristics of Pelinus linteus strain (Phellinus linteus).

Figure 2 is a flow chart showing the process of cultivation, extraction and purification of the Felinus linteus strain.

Figure 3 shows the results of gas chromatography analysis of the constituent monosaccharides of the polysaccharide extracted, separated and purified from Felinus linteus.

4 is an elution diagram showing the results of HW65F gel chromatography of polysaccharides extracted, separated and purified from Felinus linteus.

FIG. 5 shows the results of analysis of carbon nuclear magnetic resonance spectra of polysaccharides extracted, separated and purified from Felinus linteus.

6 is a graph showing the anticancer activity of polysaccharides against cancer cells derived from mice according to the polysaccharide administration method.

Figure 7a is a graph showing the anticancer activity of cancer cells derived from mouse by polysaccharide and 0.1mg / kg of adriamycin treatment.

Figure 7b is a graph showing the anticancer activity of cancer cells derived from mouse by polysaccharide and 0.3mg / kg of adriamycin treatment.

Figure 8a is a graph showing the change in size of cancer cells derived from the human body by treatment with polysaccharides and adriamycin.

8B is a graph showing the final weight of cancer cells derived from human body by polysaccharide and adriamycin treatment.

9a is a graph showing the cancer metastasis inhibiting effect by adriamycin treatment.

Figure 9b is a graph showing the cancer metastasis inhibitory effect by the combination treatment of adriamycin and polysaccharides.

Figure 10 is a graph showing the cytotoxicity after treatment of cancer cells with adriamycin and polysaccharides.

The present invention comprises the steps of culturing Pelinus linteus Yoo KCTC 0399BP; Hot water extraction, ethanol extraction and dialysis of the cultured mycelia to obtain a polysaccharide material; Performing DEAE-cellulose and gel filtration chromatography sequentially to obtain an active fraction; Analyzing the monosaccharide material constituted by gas chromatography of the polysaccharide material; Analyzing the structure of the polysaccharide material by gel column chromatography and carbon nuclear magnetic resonance spectra; Transplanting mouse-derived skin cancer cells into the mouse, administering a polysaccharide substance, and examining the survival rate of the mouse; Implanting skin cancer cells derived from the mouse into the mouse and administering anticancer agents such as adriamycin and the polysaccharide material to identify anticancer activity; Implanting human-derived cancer cells into nude mice and administering a polysaccharide substance and adriamycin to investigate anticancer effects; Implanting mouse-derived skin cancer cells into the tail vein of the mouse and administering a polysaccharide substance to investigate the cancer metastasis inhibiting effect; Mouse skin cancer cells and human lung cancer cells are treated with polysaccharides and adriamycin, followed by measuring cytotoxicity against cancer cells by measuring living cells by Sulforhominamine B (Sulforhodamin B).

Hereinafter, the specific method of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to these Examples.

Example 1 Culture of Felinus Linteus Strains

The strain of Pelinus linteus Yoo (KCTC 0399BP) deposited at the Korea Institute of Science and Technology, Genetic Resources Center, Korea Institute of Science and Technology, 50g of glucose, 10g of peptone, 10g of yeast extract, and 10g of KH ₂ PO ₄ 0.8g ₁ g of inorganic salt solution containing 0.5 g of MgSO ₄ · 7H ₂ O and 0.3 g of CaCl ₂ was incubated in a sterile liquid medium having a pH of 6.0. At this time, the liquid medium was used to make 3.5ℓ using a 5L fermenter and the culture was carried out for 11 days at a temperature of 28 ℃, aeration rate 2vvm, rotation speed 160rpm. As a result, as shown in Figure 1 mycelial yield was the highest 30g per liter after 5 days.

Example 2: Polysaccharide Extraction

280 g of the cultured mycelia obtained in Example 1 were extracted with hot water and concentrated to obtain 3 g of hot water extract. Ethanol was added to the extract so that the ethanol concentration was 80%, left at 4 ° C. for 24 hours, and centrifuged to obtain a supernatant and a precipitate. The precipitate was dissolved in water and dialyzed using a dialysis membrane (cellulose tubing, manufactured by Nippon Samgwang Pure Chemical Co., Ltd.) while exchanging the dialysate at intervals of 12 hours for 72 hours at 10 ° C. The inner solution in the dialysis membrane was lyophilized to obtain 2.45 g of crude extract.

Example 3: Purification with Pure Active Fraction

The crude extract obtained in Example 2 was dissolved in 5 mM sodium phosphate buffer (pH 7.2), titrated on a DEAE-cellulose column, washed with the same buffer, and then prepared with sodium gradient at a concentration of 0 to 1 mol in the same buffer as a gradient. Eluted at a flow rate of 5 ml per minute, 15 ml were aliquoted into each test tube. Sugar content was determined by the phenol-sulfuric acid quantitative method, and protein content was determined by the Bradford method. The crude extract fractions obtained at this time were subjected to Toyopearl HW 65F gel filtration chromatography to obtain pure active fractions with uniform molecular weight and the same properties. At this time, elution was performed with water. The procedure of Example 1, Example 2 and Example 3 is shown in FIG.

Example 4 Investigation of Constituent Sugar and Composition Ratio of Polysaccharide Materials

2 mg of each of the extracted fraction polysaccharides obtained in Example 3 was hydrolyzed with 2N TFA, reduced with sodium braid (NaBH ₄ ), acetic acid with anhydrous acetic acid to make aditol acetate, and gas chromatography was performed. Was carried out. At this time, the conditions of the column were initially maintained at 200 ° C. for 2 minutes, and the temperature was increased by 4 ° C. at 1 minute intervals so that the final temperature was maintained at 250 ° C. for 2 minutes. The temperature of the detector was 260 ° C., The temperature of the injector was maintained at 250 ° C. The instrument used was Hewlett-Packard (HP 5890 GC) and the column was used a fused silica capillary column sp-2330 (0.32mm X 30m). Carbohydrates were measured by the phenol-sulfuric acid method and protein was determined by the polyline-phenol method. As shown in FIG. 3, mannose, galactose, and glucose were sequentially identified, and the contents are summarized in Table 1.

Compositional sugars and composition ratios of polysaccharides Extraction fraction polysaccharide carbohydrate (%) protein (%) Composition sugar (% molar) Glucose Mannose Galactose PL-2 82.7 17.3 78.6 18.0 3.4

Example 5 Structural Investigation of Polysaccharides

The purity of PL-2, the extract fraction polysaccharide of Example 4, was confirmed by HW65F gel column chromatography. As a result, it can be seen that PL-2 is pure because it shows a single symmetric peak as shown in FIG. As a result of carbon nuclear magnetic resonance spectral analysis, galactomanno in which mannose and galactose are attached to long chain binding forms of glucose monosaccharides of alpha (1 → 4) and beta (1 → 6) types, as shown in FIG. It was confirmed that it is glucan (Galactomannoglucan).

Example 6: Investigation of anticancer activity against cancer cells of polysaccharide material according to the administration method

The anticancer activity of polysaccharides was measured using B16F10 skin cancer cells, which are cancer cells derived from mice. B16F10 skin cancer cells were cultured in RPMI1640 medium containing 10% serum and passaged twice a week. B16F10 skin cancer cells were implanted intraperitoneally with 100,000 cells per BDF1 mouse and the survival rate of the mice was examined for 30 days. Next, the pretreatment method was continuously administered intraperitoneally until 12 days after the cancer cell transplantation from one week before the cancer cell transplantation. Post survival was examined. As a result, as shown in FIG. 6, the survival rate of the untreated group was the lowest, and the next was the polysaccharide post-treatment group, followed by the polysaccharide pretreatment group. This is summarized in Table 2. The average survival rate of mice transplanted with B16F10 skin cancer cells was 20.8 days, the preservation of polysaccharides was 29 days, and the post-treatment of polysaccharides was 25.8 days. There was no change in weight at this time.

Immunotherapy of Polysaccharides Experimental group Average survival rate ratio Number of Surviving Animals on Day 30 (Marine) Untreated 20.8 days 100% 0/10 Polysaccharide Pretreatment Group (100mg / kg) 29.0 days or more 139% or more 8/10 Polysaccharides post-treatment group (100mg / kg) More than 25.8 days 124% or more 2/10

Example 7 Investigation of Anticancer Activity of Cancer Cells of Polysaccharide Substances in Combination with Immunochemotherapeutic

Experimental Example 1: Investigation of anticancer activity by coadministration of adriamycin and polysaccharides

The allograft test system of B16F10 skin cancer cells was used to measure the anticancer activity of the combination of polysaccharides and adriamycin. Skin cancer cells were implanted into the abdominal cavity. Adriamycin was intraperitoneally treated for 12 days after transplanting the cancer cells, and the polysaccharide material was intraperitoneally treated for 12 days after the cancer cells were transplanted 7 days before the cancer cells were transplanted. Survival of the animals was measured daily for 60 days. The adriamycin used here used a low concentration without toxicity. As a result, as shown in Fig. 7a and 7b, the survival rate of the untreated group was drastically decreased, and the survival rate was significantly increased compared to the untreated group when the polysaccharide material alone was treated. In the case of treatment with adriamycin at a concentration of 0.1 mg / kg in FIG. 7A and the treatment with a concentration of 0.3 mg / kg in FIG. 7B, the treatment with 0.3 mg / kg showed a much higher survival rate. In some cases, the use of 0.3 mg / kg may improve survival rate of mice rather than 0.1 mg / kg of adriamycin. The results are summarized in Table 3. The average survival rate of mice transplanted with B16F10 skin cancer was 18.1 days, and the average survival rate of mice treated with polysaccharides alone increased to 31 days. Treatment with adriamycin at a concentration of 0.1 mg / kg resulted in an average survival rate of 35.4 days in mice and an increase of more than 46.9 days in combination with polysaccharides. When Adriamycin was treated at a concentration of 0.3 mg / kg, the average survival rate of mice was 40.1 days or more and increased to 57.8 days or more by the combination of polysaccharides. At this time, the weight of the mouse did not decrease.

Immunochemical Anticancer Effect by Combination Treatment of Adriamycin and Polysaccharides Experimental group Average survival rate ratio(%) 60 animals survived on day 60 Untreated 18.1 100.0 0/10 Polysaccharides (100 mg / kg) 31.0 171.3 0/10 Adriamycin (0.1 mg / kg) Adriamycin (0.1 mg / kg) + Polysaccharide (100 mg / kg) 35.4 46.9 or later 195.6 259.1 or later 0/10 4/10 Adriamycin (0.3 mg / kg) Adriamycin (0.3 mg / kg) + Polysaccharide (100 mg / kg) 40.1 or more 57.8 or more 240.9 or more 319.3 or more 2/10 9/10

Experimental Example 2: Investigation of anticancer activity according to co-administration of mitomycin C and polysaccharides

In order to measure the anticancer activity of the combination of polysaccharides and mitomycin seed, allograft test system of B16F10 skin cancer cells was used as in Experiment 1 and skin cancer cells were transplanted into the abdominal cavity. Maitomycin treated with the abdominal cavity for 12 days after transplanting the cancer cells, and the polysaccharide material was treated with the abdominal cavity for 12 days after transplanting the cancer cells seven days before the cancer cell transplant. Survival of the animals was measured daily for 60 days. The mitomycin seeds used here used low concentrations without toxicity. As a result of the experiment, similar to Experimental Example 1, the survival rate of the untreated group was drastically reduced, and when treated with polysaccharides alone, the survival rate was significantly increased than that of the untreated group. The results are summarized in Table 4. The average survival rate of mice transplanted with B16F10 skin cancer was 18.1 days, and the average survival rate of mice treated with polysaccharide alone increased to 31 days. Treatment with mitomycin seed at a concentration of 0.2 mg / kg resulted in an average survival rate of 32.5 days in mice, and increased to more than 43.5 days in combination with polysaccharides. Treatment with mitomycin seed at a concentration of 0.6 mg / kg resulted in an average survival rate of more than 38.0 days and increased to more than 51.5 days by co-treatment of polysaccharides. At this time, the weight of the mouse did not decrease.

Immunochemical Anticancer Effects by Combination Treatment of Mitomycin Seed and Polysaccharides Experimental group Average survival rate ratio(%) 60 animals survived on day 60 Untreated 18.1 100.0 0/10 Polysaccharides (100 mg / kg) 31.0 171.3 0/10 Mytomycin Seed (0.2mg / kg) Mytomycin Seed (0.2mg / kg) + Polysaccharide (100mg / kg) 32.5 43.5 or more 179.6 240.3 or more 0/10 3/10 Mytomycin (0.6mg / kg) Mytomycin (0.6mg / kg) + Polysaccharide (100mg / kg) 38.0 or more 51.5 or more 209.9 or more 284.5 or more 1/10 7/10

Experimental Example 3: Investigation of anticancer activity by cisplatin and polysaccharide combination

In order to measure the anticancer activity by the combination treatment of polysaccharides and cisplatin, the allograft test system of B16F10 skin cancer cells was used in the same manner as in the experimental example, and the skin cancer cells were transplanted into the abdominal cavity. Cisplatin was intraperitoneally treated for 12 days after transplanting the cancer cells, and polysaccharides were intraperitoneally treated for 12 days after the cancer cells were transplanted 7 days before the cancer cells were transplanted. Survival of the animals was measured daily for 60 days. The cisplatin used here was low in toxicity. Experimental results showed that, similarly to the experimental examples, the survival rate of the untreated group was drastically decreased, and the survival rate was significantly increased compared to the untreated group when the polysaccharide material was treated alone. The results are summarized in Table 5. Treatment with cysplatin at a concentration of 0.5 mg / kg resulted in an average survival rate of 33.0 days in mice, and increased to more than 44.0 days in combination with polysaccharides. Treatment with cysplatin at a concentration of 1.5 mg / kg resulted in an average survival rate of more than 40.5 days and increased to more than 52.6 days by the combination of polysaccharides. At this time, the weight of the mouse did not decrease.

Immunochemical Anticancer Effect by Combination Treatment of Cysplatin and Polysaccharides Experimental group Average survival rate ratio(%) 60 animals survived on day 60 Untreated 18.1 100.0 0/10 Polysaccharides (100 mg / kg) 31.0 171.3 0/10 Cisplatin (0.5mg / kg) Cisplatin (0.5mg / kg) + Polysaccharide (100mg / kg) 33.0 44.0 or more 182.3 243.0 or later 0/10 3/10 Cisplatin (1.5mg / kg) Cisplatin (1.5mg / kg) + Polysaccharide (100mg / kg) 40.5 or more 52.6 or more 223.8 or more 290.6 or more 2/10 7/10

Experimental Example 4: Investigation of anticancer activity according to the co-administration of 5-Fleuoro uracil polysaccharides

In order to measure the anticancer activity by the combination of polysaccharides and 5-fluorouracil, the allograft test system of B16F10 skin cancer cells was used in the same manner as the experimental example, and the skin cancer cells were transplanted into the abdominal cavity. 5-fluorouracil was intraperitoneally treated for 12 days after transplanting the cancer cells, and polysaccharides were intraperitoneally treated for 12 days after the cancer cells were transplanted 7 days before the cancer cells were transplanted. Survival of the animals was measured daily for 60 days. The 5-fluorouracil used here used a low concentration without toxicity. Experimental results showed that, similarly to the experimental examples, the survival rate of the untreated group was drastically reduced, and the survival rate was significantly increased when the polysaccharide material alone was treated. The results are summarized in Table 6. Treatment with 5-fluorouracil at a concentration of 1 mg / kg resulted in an average survival rate of 34.2 days in mice, and increased to more than 45.5 days when combined with polysaccharides. When 5-fluorouracil was treated at a concentration of 3 mg / kg, the average survival rate of mice was 40.2 days or more, and increased to 54.8 days or more by co-treatment of polysaccharides. At this time, the weight of the mouse did not decrease.

Immunochemical Anticancer Effects by Combination Treatment of 5-Floruracil and Polysaccharides Experimental group Average survival rate ratio(%) 60 animals survived on day 60 Untreated 18.1 100.0 0/10 Polysaccharides (100 mg / kg) 31.0 171.3 0/10 5-fluorouracil (1mg / kg) 5-fluorouracil (1mg / kg) + polysaccharide (100mg / kg) 33.0 44.0 or more 187.8 251.4 or more 0/10 4/10 5-fluorouracil (3mg / kg) 5-fluorouracil (3mg / kg) + polysaccharide (100mg / kg) 40.5 or more 52.6 or more 222 or more 302.0 or more 2/10 8/10

Example 8 Investigation of Anticancer Effect of Polysaccharides on Human-Derived Cancer Cells

The immune anticancer activity of polysaccharides against human derived cancer cells was verified using NCl-H23 lung cancer cells. NCl-H23 lung cancer cells were implanted subcutaneously into nude mice and polysaccharides and adriamycin were administered intraperitoneally for 12 days after cancer cell transplantation. The size of the cancer cells was measured, and cancer was isolated and weighed 19 days after cancer cell transplantation. Nude mice are deficient in T cells, and their antitumor activity is mainly caused by natural killer cells or macrophages. Therefore, anticancer activity by polysaccharides is mediated by these two kinds of immune cells. As a result, as shown in Fig. 8a and 8b, the size of the cancer cells was the largest increase in the untreated group, followed by polysaccharides and adriamycin, the weight was also decreased in the order of untreated group, polysaccharides, adriamycin. The results are summarized in Tables 7 and 8. The weight of the mice used at this time did not change.

Immune anticancer effect on human-derived cancer cells (cancer size change, mm ³ ) Experimental group Day 14 Day 17 Day 18 Day 19 Untreated group polysaccharide (100 mg / kg) adriamycin (1 mg / kg) 43 20 12 105 39 27 131 40 34 158 43 33

Immune anticancer effect on human derived cancer cells Experimental group Final weight (mg) Untreated group polysaccharide (100 mg / kg) adriamycin (1 mg / kg) 259 113 95

Example 9: Inhibition of metastasis of mouse-derived cancer cells by polysaccharides

B16F10 skin cancer cells were implanted into C57BL / 6 mice with tail vein in order to measure the effect of inhibiting cancer metastasis by the polysaccharide material of the present invention, and the lungs were separated on day 14 to verify the degree of cancer metastasis. Polysaccharides were administered 7 days before cancer transplantation and were administered intraperitoneally for 12 days after cancer transplantation. Adriamycin was administered intraperitoneally for 12 days after cancer transplantation. As a result, metastasis occurred due to tail vein injection of B16F10 skin cancer cells, forming dark spots on the lungs. As shown in FIG. 9A, about 272 dark spots were formed in the untreated drug group, and the number of spots was reduced to 197 by treatment with 1 mg / kg of adriamycin and the number of spots was 172 by 3 mg / kg of adriamycin. Decreased. In the case of Example 7, adriamycin inhibited the growth of cancer cells at concentrations of 0.3 to 0.1 mg / kg, but cancer metastasis was very weak at higher concentrations of 3 mg / kg to 1 mg / kg. As shown in FIG. 9B, the number of spots was reduced to 83 by polysaccharide treatment alone, and the number of spots was 136 and 131 in the combination treatment group with adriamycin. This result indicates that treatment of polysaccharides is necessary to suppress cancer metastasis. These results are summarized in Table 9.

Cancer metastasis inhibitory effect of polysaccharides Test group Number of spots Untreated group polysaccharide (100 mg / kg) adriamycin (1 mg / kg) adriamycin (1 mg / kg) + polysaccharide (100 mg / kg) adriamycin (3 mg / kg) adriamycin (3 mg / kg) + polysaccharide (100 mg / kg) 272 83 197 136 172 131

Example 10 Determination of Direct Toxicity of Cancer Cells with Polysaccharides

Experiments were conducted to determine whether the anti-cancer effect mediated immune enhancement or direct toxicity to cancer cells. B16F10 mouse skin cancer cells and NCl-H23 human lung cancer cells were directly treated with polysaccharides and adriamycin. Treatment concentrations ranged from 0.3 μg / kg to 30 μg / kg and after 2 days of treatment, the amount of viable cells was determined by Sulforhodamin B assay. The amount of viable cells of the experimental group without drug treatment was expressed as 100% and the amount of drug treated group cells was expressed as a ratio. As a result, as shown in FIG. 10, adriamycin showed strong cytotoxicity against two types of cancer cells, and polysaccharide did not show cytotoxicity. This suggests that adriamycin is an anticancer agent that mediates cytotoxicity and that the polysaccharide material is an immune anticancer agent that has an anticancer effect by increasing the immune function of a living body. These results are summarized in Table 10.

Direct toxicity of cancer cells to polysaccharides (%) Experimental group Adriamycin Polysaccharides B16F10 NCl-H23 B16F10 NCl-H23 Untreated group 0.3 µg / ml 1 µg / ml 3 µg / ml 10 µg / ml 30 µg / ml 100 56 29 9 -10 -10 100 100 71 39 7 -1 100 93 89 80 78 77 100 93 89 80 78 77

Example 11 Assay of Effect as AIDS Prevention or Treatment Aid

As a result of the prophylactic or therapeutic effect of acquired immunodeficiency syndrome (AIDS) by the polysaccharide material of the present invention, it was confirmed that it is effective as a prophylactic and therapeutic aid of AIDS.

As described in the above embodiments, the present invention has the effect of separating new polysaccharides from Pelinus linteus Yoo, and the polysaccharides have an effect of inhibiting cancer metastasis by increasing the immune function of the body as an anticancer drug. Able to know. Therefore, this polysaccharide is effective for the prevention and treatment of immune-related diseases such as cancer and AIDS, and can be used as a drug for basic mechanism research.

Claims (2)

Use of polysaccharides isolated from the genus Felinus as an immune chemotherapy. Use of immuno-cancer polysaccharides isolated from Felinus linteus as adjuvant therapy for immune or related diseases including cancer or AIDS.